Patents by Inventor Fang-Jie Zhang

Fang-Jie Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminoheteroaryl compounds as protein kinase inhibitors
    Patent number: 8106197
    Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: January 31, 2012
    Assignee: Pfizer Inc.
    Inventors: Jingrong Jean Cui, Dilip Bhumralkar, Iriny Botrous, Ji Yu Chu, Lee A. Funk, Cathleen Elizabeth Hanau, G. Davis Harris, Lei Jia, Joanne Johnson, Stephen A. Kolodziej, Pei-Pei Kung, Xiaoyuan (Sharon) Li, Jason (Qishen) Lin, Jerry Jialun Meng, Mitchell David Nambu, Christopher G. Nelson, Mason Alan Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
  • Aminoheteroaryl compounds as protein kinase inhibitors
    Patent number: 7230098
    Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: June 12, 2007
    Assignee: Sugen, Inc.
    Inventors: Jingrong Jean Cui, Dilip Bhumralkar, Iriny Botrous, Ji Yu Chu, Lee A. Funk, Cathleen Elizabeth Hanau, G. Davis Harris, Lei Jia, Joanne Johnson, Stephen A. Kolodziej, Pei-Pei Kung, Xiaoyuan (Sharon) Li, Jason (Qishen) Lin, Jerry Jialun Meng, Mitchell David Nambu, Christopher G. Nelson, Mason Alan Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
  • Aminoheteroaryl compounds as protein kinase inhibitors
    Publication number: 20070072874
    Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
    Type: Application
    Filed: November 14, 2006
    Publication date: March 29, 2007
    Inventors: Jingrong Cui, Dilip Bhumralkar, Iriny Botrous, Ji Chu, Lee Funk, Cathleen Hanau, G. Harris, Lei Jia, Joanne Johnson, Stephen Kolodziej, Pei-Pei Kung, Xiaoyuan Li, Jason Lin, Jerry Meng, Mitchell Nambu, Christopher Nelson, Mason Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
  • Triazolotriazine compounds and uses thereof
    Patent number: 7122548
    Abstract: The present invention relates to compounds of the Formula (I), and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: October 17, 2006
    Assignee: Sugen, Inc.
    Inventors: Fang-Jie Zhang, Tomas Vojkovsky, Ping Huang, Congxin Liang, Steven Huy Do, Marcel Koenig, Jingrong Cui
  • Synthetic LSD metabolite for preparing haptens used in an LSD metabolite immunoassay
    Publication number: 20060223998
    Abstract: A general method for the synthesis of OH-LSD and its analogs has been successfully developed. This method is convenient and efficient and allows preparation of a series of OH-LSD analogs with linkers attached at various (C-8, N-6 or N-1) positions.
    Type: Application
    Filed: March 30, 2005
    Publication date: October 5, 2006
    Inventors: Fang-Jie Zhang, Hshiou-ting Liu
  • Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors
    Patent number: 7105562
    Abstract: The present invention relates to certain sulfonamido-substituted geometrically restricted indolinones of the formula: wherein R1–R12 and X are variables defined herein. The sulfonamido-substituted geometrically restricted indolinones of the preferred embodiments of the present invention modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: September 12, 2006
    Assignee: Sugen, Inc.
    Inventors: Fang-Jie Zhang, Jingrong Cui, Chung Chen Wei, Peng Cho Tang
  • Tetracyclic compounds as c-Met inhibitors
    Patent number: 7037909
    Abstract: The present invention relates to compounds of the Formulae (I) and (II), wherein R1-R10 and G are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
    Type: Grant
    Filed: June 29, 2004
    Date of Patent: May 2, 2006
    Assignee: Sugen, Inc.
    Inventors: Tomas Vojkovsky, Marcel Koenig, Fang-Jie Zhang, Jingrong Cui
  • Indolinone hydrazides as c-Met inhibitors
    Publication number: 20060009493
    Abstract: The present invention relates to compounds of the formulae (I)-(XII), wherein R1-R71, A, B, X, Y, G, L and Z are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
    Type: Application
    Filed: June 25, 2004
    Publication date: January 12, 2006
    Inventors: Marcel Koenig, Jingrong Cui, Chung Wei, Steven Do, Fang-Jie Zhang, Tomas Vojkovsky, John Ramphal, Guang Yang, Matthew Mattson, Christopher Nelson, Peng Tang
  • Triazolotriazine compounds and uses thereof
    Publication number: 20050075340
    Abstract: The present invention relates to compounds of the Formula (I), and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
    Type: Application
    Filed: June 24, 2004
    Publication date: April 7, 2005
    Inventors: Fang-Jie Zhang, Tomas Vojkovsky, Ping Huang, Congxin Liang, Steven Do, Marcel Koenig, Jingrong Cui
  • 4-aryl substituted indolinones
    Patent number: 6861418
    Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: March 1, 2005
    Assignee: Sugen, Inc.
    Inventors: Jingrong Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang
  • Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors
    Publication number: 20050038066
    Abstract: The present invention relates to certain sulfonamido-substituted geometrically restricted indolinones of the formula: wherein R1-R12 and X are variables defined herein. The sulfonamido-substituted geometrically restricted indolinones of the preferred embodiments of the present invention modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Application
    Filed: August 5, 2004
    Publication date: February 17, 2005
    Inventors: Fang-Jie Zhang, Jingrong Cui, Chung Chen Wei, Peng Tang
  • Tetracyclic compounds as c-Met inhibitors
    Publication number: 20050014755
    Abstract: The present invention relates to compounds of the Formulae (I) and (II), wherein R1—R10 and G are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
    Type: Application
    Filed: June 29, 2004
    Publication date: January 20, 2005
    Inventors: Tomas Vojkovsky, Marcel Koenig, Fang-Jie Zhang, Jingrong Cui
  • Aminoheteroaryl compounds as protein kinase inhibitors
    Publication number: 20050009840
    Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
    Type: Application
    Filed: February 26, 2004
    Publication date: January 13, 2005
    Inventors: Jingrong Cui, Dilip Bhumralkar, Iriny Botrous, Ji Chu, Lee Funk, Cathleen Hanau, G. Harris, Lei Jia, Joanne Johnson, Stephen Kolodziej, Pei-Pei Kung, Xiaoyuan Li, Jason Lin, Jerry Meng, Mitchell Nambu, Christopher Nelson, Mason Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
  • 4-Aryl substituted indolinones
    Publication number: 20040157909
    Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.
    Type: Application
    Filed: December 16, 2003
    Publication date: August 12, 2004
    Applicant: Sugen, Inc.
    Inventors: Jingrong Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang
  • 4-aryl substituted indolinones
    Patent number: 6677368
    Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: January 13, 2004
    Assignee: Sugen, Inc.
    Inventors: Jingrong Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang
  • 4-aryl substituted indolinones
    Publication number: 20030069297
    Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.
    Type: Application
    Filed: December 20, 2001
    Publication date: April 10, 2003
    Applicant: Sugen, Inc.
    Inventors: Jingrong Jean Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang